We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
- Authors
Kerl, K; Prins, C; Saurat, J H; French, L E
- Abstract
Rituximab (MabThera); Roche, Basel, Switzerland; an anti-CD20 chimeric monoclonal antibody) has been shown to have significant activity in nodal B-cell lymphomas, with few associated adverse effects. Its efficacy and safety were first demonstrated in the treatment of systemic B-cell lymphomas. Intravenous and subsequently intralesional administration of rituximab have also been reported to be effective and well tolerated in cutaneous B-cell lymphoma (CBCL). The comparative efficacy of intravenous vs. intralesional rituximab in CBCL is not known.
- Publication
The British journal of dermatology, 2006, Vol 155, Issue 6, p1197
- ISSN
0007-0963
- Publication type
Journal Article
- DOI
10.1111/j.1365-2133.2006.07523.x